Advertisement

Chronisch-entzündliche Darmerkrankungen (CED)

  • Michael Friedt
  • Christian P. Braegger

Zusammenfassung

Inzidenz und Prävalenz der CED haben in den vergangenen zwei Jahrzehnten sowohl im Kindesalter als auch bei Erwachsenen zugenommen. Verglichen mit dem Zeitraum 1990–1992 wurde in Schweden ein signifikanter Anstieg der Inzidenz des M. Crohn von 1,7 erkrankten Kindern pro 100.000 Einwohner auf 8,4 / 100.000 in den Jahren 1999–2001 beobachtet. Die zunehmende Inzidenz der CED bei Kindern und Jugendlichen ist nicht die Folge eines zunehmend früheren Krankheitsbeginns, sondern Ausdruck einer zunehmenden Inzidenz in allen Altersklassen. Aus Großbritannien, Australien, Schweden und den USA zeigen Studien Folgendes: Die Inzidenz des M. Crohn liegt zwischen 1,3 und 6 pädiatrischen Patienten pro 100.000 Einwohner. Die klinische Manifestation der CED erfolgt bei bis zu 30 % aller Patienten bereits vor dem 18. Lebensjahr. Vereinzelte Fallberichte und kleinere Studien zeigen, dass ein Erkrankungsbeginn bereits in den ersten Lebensjahren möglich ist. Heyman et al. (2005) berichten, dass etwa 60 % der bis zum Alter von 18 Jahren erkrankten Kinder bereits vor ihrem 12. Lebensjahr erkranken und 9 % bereits vor dem 5. Lebensjahr.

Literatur

Literatur zu Abschn. 11.1

  1. Armitage E, Drummond H, Ghosh S, Ferguson A (1999) Incidence of juvenile-onset Crohn’s disease in Scotland. Lancet 353: 1496–1497PubMedGoogle Scholar
  2. Baldassano R, Braegger CP, Escher JC et al. (2003) Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 98: 833–838PubMedGoogle Scholar
  3. Baldassano RN, Han PD, Jeshion WC et al. (2001) Pediatric Crohn’s disease: risk factors for postoperative recurrence. Am J Gastroenterol 96: 2169–2176PubMedGoogle Scholar
  4. Binder V, Orholm M (1996) Familial occurrence and inheritance studies in inflammatory bowel disease. Neth J Med 48: 53–56PubMedGoogle Scholar
  5. Bourreille A, Ignjatovic A, Aabakken L et al. (2009) Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 41: 618–637PubMedGoogle Scholar
  6. Braegger CP, MacDonald TT (1994) Immune mechanisms in chronic inflammatory bowel disease. Ann Allergy 72: 135–41PubMedGoogle Scholar
  7. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339: 89–91PubMedGoogle Scholar
  8. Braegger CP, Ballabeni P, Rogler D et al., Swiss IBD Cohort Study Group (2011) Epidemiology of inflammatory bowel disease: is there a shift towards onset at a younger age? J Pediatr Gastroenterol Nutr 53: 141–144PubMedGoogle Scholar
  9. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT (1993) Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 78: 127–131PubMedGoogle Scholar
  10. Cezard JP, Touati G, Alberti C et al. (2002) Growth in paediatric Crohn’s disease. Horm Res 58 (Suppl 1): 11–15PubMedGoogle Scholar
  11. Cho JH, Brant SR (2011) Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140: 1704–1712PubMedGoogle Scholar
  12. Bie CI de, Buderus S, Sandhu BKet al., EUROKIDS Porto IBD Working Group of ESPGHAN (2012) Diagnostic workup of paediatric inflammatory bowel disease patients in Europe: results of a 5-year audit of the EUROKIDS registry. J Pediatr Gastroenterol Nutr 53(3): 374–380Google Scholar
  13. Escher JC, Taminiau JAJM, Nieuwenhuis EES, Büller HA, Grand RJ (2003) Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 9: 34–58PubMedGoogle Scholar
  14. Faubion WA Jr, Loftus EV, Sandborn WJ, Freese DK, Perrault J (2001) Pediatric „PSC-IBD“: a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr 33: 296–300PubMedGoogle Scholar
  15. Griffiths AM, Wesson DE, Shandling B, Corey M, Sherman PM (1991) Factors influencing postoperative recurrence of Crohn’s disease in childhood. Gut 32: 491–495PubMedGoogle Scholar
  16. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR (1995) Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology 108: 1056–1067PubMedGoogle Scholar
  17. Griffiths AM, Otley AR, Hyams J et al. (2005) A review of activity indices and end points for clinical trials in children with Crohn’s disease. Inflamm Bowel Dis 11(2): 185–96PubMedGoogle Scholar
  18. Henderson P, Hansen R, Cameron FL et al. (2011) Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis. doi: 10.1002/ibd.21797Google Scholar
  19. Heuschkel RB, Menache CC, Megerian JT, Baird AE (2000) Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr 31: 8–15PubMedGoogle Scholar
  20. Heyman MB, Kirschner BS, Gold BD et al. (2005) Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 146: 35–40PubMedGoogle Scholar
  21. Hildebrand H, Berg NO, Hoevels J, Ursing B (1980) Treatment of Crohn’s disease with metronidazole in childhood and adolescence. Evaluation of a six months trial. Gastroenterol Clin Biol 4: 19–25PubMedGoogle Scholar
  22. Hildebrand H, Finkel Y, Grahnquist L et al. (2003) Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990–2001. Gut 52: 1432–1434PubMedGoogle Scholar
  23. Hyams JS (1994) Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 19: 7–21PubMedGoogle Scholar
  24. Hyams JS, Ferry GD, Mandel FS et al. (1991) Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 12: 439–447PubMedGoogle Scholar
  25. Kim SJ, Ferry GD (2004) Inflammatory bowel disease in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 126: 1550–1560PubMedGoogle Scholar
  26. Levine A, Milo T, Buller H, Markowitz J (2003) Consensus and controversy in the management of pediatric Crohn disease: an international survey. J Pediatr Gastroenterol Nutr 36: 464–469PubMedGoogle Scholar
  27. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F (2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 119: 895–902PubMedGoogle Scholar
  28. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F (1990) Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology 99: 1347–1351PubMedGoogle Scholar
  29. Mowat C, Cole A, Windsor A et al., IBD Section of the British Society of Gastroenterology (2011) Guidelines for the management of inflammatory bowel disease in adults. Gut 60: 571–607PubMedGoogle Scholar
  30. Newby EA, Sawczenko A, Thomas AG, Wilson D (2005) Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev 20 (3): CD003873Google Scholar
  31. Orholm M, Munkholm P, Langholz E et al. (1991) Familial occurrence of inflammatory bowel disease. N Engl J Med 324: 84–88PubMedGoogle Scholar
  32. Pearson DC, May GR, Fick G, Sutherland LR (2000) Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev: CD000067Google Scholar
  33. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347: 417–429PubMedGoogle Scholar
  34. Sandborn W, Sutherland L, Pearson D et al. (2000) Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev: CD000545Google Scholar
  35. Sandhu BK, Fell JME et al., IBD Working Group of the British Society of Paediatric Gastroenterology, Hepatology and Nutrition (2010) Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 50: S1–S13Google Scholar
  36. Thomas AG, Taylor F, Miller V (1993) Dietary intake and nutritional treatment in childhood Crohn’s disease. J Pediatr Gastroenterol Nutr 17: 75–81PubMedGoogle Scholar
  37. Vavricka S, Spigaglia S, Rogler D et al., Swiss IBD cohort Study Group (2012) Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 18(3): 496–505PubMedGoogle Scholar
  38. Verhave M, Winter HS, Grand RJ (1990) Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 117: 809–814PubMedGoogle Scholar

Literatur zu Abschn. 11.2

  1. Actis GC, Fadda M, Pellicano R et al. (2009) The 17-year single-center experience with the use of azathioprine to maintain remission in ulcerative colitis. Biomed Pharmacother 63: 362–365PubMedGoogle Scholar
  2. Armstrong RG, West J, Card TR (2010) Rsik of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 105: 1604–1609PubMedGoogle Scholar
  3. Auvin S, Moline F, Gower-Rousseau C et al. (2005) Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in Northern France. J Pediatr Gastroenterol Nutr 41: 49–55PubMedGoogle Scholar
  4. Baars JE, Looman CWN, Sreyerberg EW et al. (2011) The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 106: 319–328PubMedGoogle Scholar
  5. Baumgart DC, Wiedenmann B, Dignass AU (2003) Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 17: 1273–1281PubMedGoogle Scholar
  6. Beattie RM, Walker-Smith JA, Murch SH (1995) Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 73: 354–355PubMedGoogle Scholar
  7. Belluzzi A, Serrani M, Roda G et al. (2010) Pilot study: the use of sulfasalazine for the treatment of acute pouchitis. Aliment Pharmacol Ther 31: 228–232PubMedGoogle Scholar
  8. Benchimol EI, Guttmann A, Griffiths AM et al. (2009) Increasing incidence of paediatric inflammatory bowel disease. Gut 58: 1490–1497PubMedGoogle Scholar
  9. Biancone L, Michetti P, Travis S et al. (2008) European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Col 2: 63–92Google Scholar
  10. Bodegraven AA van, Mulder CJ (2006) Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol 12: 6115–6123PubMedGoogle Scholar
  11. Campbell S, Ghosh S (2001) Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol 13: 1073–1076PubMedGoogle Scholar
  12. Caprilli R, D’Ovidio V (2007) Leucocytapheresis as promising therapy for inflammatory bowel disease. Dig Liv Dis 39: 435–437Google Scholar
  13. Cassinotti A, Actis GC, Duca P et al. (2009) Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 104: 2760-2767PubMedGoogle Scholar
  14. Castro M, Papadatou B, Baldassare M (2008) Inflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register (1996–2003). Inflamm Bowel Dis 14: 1246–1252PubMedGoogle Scholar
  15. Cho JH (2004) Advances in the genetics of inflammatory bowel disease. Curr Gastroenterol Rep 6: 467–473PubMedGoogle Scholar
  16. Chucchiara S, Escher JC, Hildebrandt H et al. (2009) Pediatric inflammatory bowel disease and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 48: 257–267Google Scholar
  17. Cuthbert AP, Fisher SA, Mirza MM et al. (2002)The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 70: 845–857Google Scholar
  18. D’Haens GR, Panaccione R, Higgins PDR et al. (2011) The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the ECCO: When to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106: 199–122PubMedGoogle Scholar
  19. Davies YK, Cox KM, Abdullah BA et al. (2008) Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 47: 61–67PubMedGoogle Scholar
  20. Deneau M, Adler DG, Schwartz JJ et al. (2011) Cholangiocarcinoma in a 17-year-old boy with primary sclerosing cholangitis and inflammatory bowel disease. J Pediatr Gastroenterol Nutr 52: 617–620PubMedGoogle Scholar
  21. Dignass A, Preiß JC, Aust D et al. (2011) Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 – Ergebnisse einer Evidenzbasierten Konsensuskonferenz. Z Gastroenterol 49: 1276–1341PubMedGoogle Scholar
  22. Dotson JL, Hyams JS, Markowitz J et al. (2010) Extraintestinal manifestations of pediatric inflammatory bowel disease and their relations to disease type and severity. J Pediatr Gastroenterol Nutr 51: 140–145PubMedGoogle Scholar
  23. Durno C, Sherman P, Harris K et al. (1998) Outcome after ileoanal anastomosis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr 27: 501–507PubMedGoogle Scholar
  24. Eaden JA, Abrams KA, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526–535PubMedGoogle Scholar
  25. Eidelwein AP, Cuffari C, Abadom V et al. (2005) Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 11: 213–218PubMedGoogle Scholar
  26. Engstrom I (1999) Inflammatory bowel disease in children and adolescents: mental health and family functioning. J Pediatr Gastroenterol Nutr 28 (Suppl 4): S28–S33Google Scholar
  27. Escher JC (2006) Diagnostic work-up and disease phenotype on pediatric IBD: 2-year results from the ESPGHAN registry. J Pediatr Gastroenterol Nutr 43 (Suppl 2): 8–10Google Scholar
  28. Escher JC, Dias JA, Bochenek K et al. (2005) Inflammatory bowel disease in children and adolescents: recommendations for diagnosis – The Porto criteria. J Pediatr Gastroenterol Nutr 41: 1–7Google Scholar
  29. Fagerberg UL, Loof L, Lindholm J et al. (2007) Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 45: 414–420PubMedGoogle Scholar
  30. Fanjiang G, Russell GH, Katz AJ (2007) Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 44: 312–317PubMedGoogle Scholar
  31. Felder JB, Korelitz BI, Rajapakse R et al. (2000) Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 95: 1949–1954PubMedGoogle Scholar
  32. Feldstein AE, Perrault J, El-Youssif M et al. (2003) Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 38: 210–217PubMedGoogle Scholar
  33. Fellermann K, Tanko Z, Herrlinger KR et al. (2002) Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 8: 317–324Google Scholar
  34. Gionchetti P, Rizzello F, Venturi A et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305–309PubMedGoogle Scholar
  35. Gisbert JP, Gonzalez-Lama Y, Mate J (2006) Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 25: 19–37Google Scholar
  36. Gisbert JP, Linares PM, McNicholl AG et al. (2009) Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 30: 126–137PubMedGoogle Scholar
  37. Gold N, Issenman R, Roberts J et al. (2000) Well-adjusted children: an alternate view of children with inflammatory bowel disease and functional gastrointestinal complaints. Inflamm Bowel Dis 6: 1–7PubMedGoogle Scholar
  38. Griffiths AM (2004) Specificities in inflammatory bowel disease in childhood. Best Pract Clin Gastroenterol 18: 509–523Google Scholar
  39. Harris MS, Lichtenstein GR (2011) Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalamine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther 33: 996–1009PubMedGoogle Scholar
  40. Henriksen M, Jahnsen J, Sauar J et al. (2006) Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 12: 543–550PubMedGoogle Scholar
  41. Ho GT, Lee HM, Brydon B et al. (2009) Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 104: 673–678PubMedGoogle Scholar
  42. Hyams JS, Davis P, Grancher K et al. (1996) Clinical outcome of ulcerative colitis in children. J Pediatr 129: 81–88PubMedGoogle Scholar
  43. Ikeda H, Ishimaru Y, Takayasu H (2006) Efficacy of granulocyte apheresis in pediatric patients with ulcerative colitis: a pilot study. J Pediatr Gastroenterol Nutr 43:592–596PubMedGoogle Scholar
  44. Jacobstein DA, Markowitz JE, Kirschner BS et al. (2005) Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 11: 442–446PubMedGoogle Scholar
  45. Joishy M, Davies I, Ahmed M et al. (2009) Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 48: 48–54PubMedGoogle Scholar
  46. Jose FA, Garnett EA, Vittinghoff E et al. (2009) Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 15: 63–68PubMedGoogle Scholar
  47. Kaguthasan S, Judd RH, Hoffmann RG et al. (2003) Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 143: 525–531Google Scholar
  48. Kappelmann MD, Rifas-Shiman SL, Kleinman K et al. (2007) The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 5: 1424–1429Google Scholar
  49. Kirschner BS (1998) Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115: 813–821PubMedGoogle Scholar
  50. Kleinman RE, Baldassano RN, Caplan A et al. (2004) Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the NASPGHAN. J Pediatr Gastroenterol Nutr 39: 15–27PubMedGoogle Scholar
  51. Kotlyar DS, Osterman MT, Diamond RH et al. (2011) A systematic review of factors that contribute o hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 9: 36–41PubMedGoogle Scholar
  52. Kruis W, Fric P, Pokroniets J et al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617–1623PubMedGoogle Scholar
  53. Kruis W, Dignass A, Steinhagen-Thiessen et al. (2005) Open label trial of granuolcyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 11: 7001–7006PubMedGoogle Scholar
  54. Kruis W, Kiudelis G, Racz I et al. (2009) Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 58: 233–240PubMedGoogle Scholar
  55. Langholz E, Munkholm P, Krasilnikoff PA et al. (1997) Inflammatory bowel disease with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 32: 139–147PubMedGoogle Scholar
  56. Lichtenstein GR, Feagan BG, Cohen RD et al. (2006) Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 4: 621–630PubMedGoogle Scholar
  57. Lichtenstein GR, Kamm MA, Sandborn WJ et al. (2008) MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther 27: 1094–1102PubMedGoogle Scholar
  58. Lindberg J, Stenling R, Palmqvist R et al. (2008) Early onset of ulcerative colitis: long-term follow-up with special reference to colorectal cancer and primary sclerosing cholangitis. J Pediatr Gastroenterol Nutr 46: 534–538PubMedGoogle Scholar
  59. Malaty HM, Fan X, Opekun AR et al. (2010) Rising incidence of inflammatory bowel disease among children: a 12 year study. J Pediatr Gastroenterol Nutr 50: 27–31PubMedGoogle Scholar
  60. Mamula P, Markowitz JE, Cohen LJ et al. (2004) Infliximab in pediatric ulcerative colitis: two year follow-up. J Pediatr Gastroenterol Nutr 38: 298–301PubMedGoogle Scholar
  61. Markowitz J, Grancher K, Kohn N et al. (2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn‘s disease. Gastroenterology 119: 895–902PubMedGoogle Scholar
  62. Martin de Carpi J, Vilar P, Prieto G et al. (2008) Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr 46: 386–391Google Scholar
  63. Maser EA, Villela R, Silverberg RA et al. (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 4: 1248–1254PubMedGoogle Scholar
  64. Masunaga Y, Ohno K, Ogawa R et al. (2007) Meta-analsyis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 41: 21–28PubMedGoogle Scholar
  65. McGovern DPB, Jewell DP (2005) Risks and benefit of azathioprine therapy. Gut 54: 1055–1059PubMedGoogle Scholar
  66. Moody G, Eaden JA, Mayberry JF (1999) Social implications of childhood Crohn‘s disease. J Pediatr Gastroenterol Nutr 28: S43–S45PubMedGoogle Scholar
  67. Mossop H, Davies P, Murphy MS (2008) Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 47: 123–129PubMedGoogle Scholar
  68. Murphy MS (2006) Immunmodulation with AZA/6-MP/MTX: current use in IBD. J Pediatr Gastroenterol Nutr 43 (Suppl 2): 24–25Google Scholar
  69. Murthy SK, Nguyen GC (2011) Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 106: 713–718PubMedGoogle Scholar
  70. Newby EA, Croft NM, Green M et al. (2008) Natural history of paediatric inflammatory bowel disease over a 5-year follow-up: retrospective review of data from the registry of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 46: 539–545PubMedGoogle Scholar
  71. Ogata H, Matsui T, Nakamura M et al. (2006) A randomised, dose-finding study of oral tacrolimus (FK 506) therapy in refractory ulcerative colitis. Gut 55: 1224–1225Google Scholar
  72. Orholm M, Munkholm P, Langholz E et al. (1991) Familial occurrence of inflammatory bowel disease. N Engl J Med 324: 84–88PubMedGoogle Scholar
  73. Oussalah A, Danese S, Peyrin-Biroulet L (2010) Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 11: 156–175PubMedGoogle Scholar
  74. Patton D, Gupta N, Wojcicki JM et al. (2010) Postoperative outcome of colectomy for pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr 51: 151–154PubMedGoogle Scholar
  75. Persley KM, Present DH (2001) Neutropenia is not required for clinical remission during azathioprine therapy in inflammatory bowel disease. Eur J Gastroenterol Hepatol 13: 1053–1055PubMedGoogle Scholar
  76. Ramakrishna J, Langhans N, Calenda K et al. (1996) Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 22: 296–302PubMedGoogle Scholar
  77. Rembacken BJ, Snelling AM, Hawkey PM et al. (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635–639PubMedGoogle Scholar
  78. Ruemmele FM (2010) Pediatric inflammatory bowel diseases: coming of age. Curr Opin Gastroenterol 26: 332–336PubMedGoogle Scholar
  79. Russo EA, Harris AW, Campbell S et al. (2009) Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther 29: 308–314PubMedGoogle Scholar
  80. Rutgeerts P, Sandborn WJ, Feagan BG (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2472PubMedGoogle Scholar
  81. Sandborn WJ (1994) Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 107: 1856–1860PubMedGoogle Scholar
  82. Sandborn WJ, McLeod R, Jewell DP (1999) Medical therapy for induction and maintenance of remission in pouchitis: a systematic review. Inflamm Bowel Dis 5: 33–39PubMedGoogle Scholar
  83. Sandborn WJ, Kamm MA, Lichtenstein GR et al. (2007) MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 26: 205–215PubMedGoogle Scholar
  84. Sandhu BK, Fell JME, Beattie RM et al. (2010) Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 50 (Suppl 1): S1–S13Google Scholar
  85. Sawczenko A, Sandhu BK (2003) Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 88: 995–1000PubMedGoogle Scholar
  86. Sawczenko A, Sandhu BK, Logan RFA et al. (2001) Prospective survey of childhood inflammatory bowel disease in the British isles. Lancet 357: 1093–1094PubMedGoogle Scholar
  87. Schürmann G, Ochman S, Neurath MF (2000) Das Colitis ulcerosa-assoziierte Kolonkarzinom. Dtsch Med Wochenschr 125: 1045–1050PubMedGoogle Scholar
  88. Socha P (2006) Efficacy and safety of cyclosporine in the treatment of IBD in children: retrospective analysis. J Pediatr Gastroenterol Nutr 43(Suppl 2): S51–S52Google Scholar
  89. Stavlo PL, Libsch KD, Rodeberg DA et al. (2003) Pediatric ileal pouch-anal anastomosis: functional outcomes and quality of life. J Pediatr Surg 38: 935–939PubMedGoogle Scholar
  90. Stein J, Hartmann F, Dignass AU (2010) Diagnosis and management of iron deficiency anemia in patiens with IBD. Nat Rev Gastroenterol Hepatol 7: 59–610Google Scholar
  91. Takemoto K, Kato J, Kuriyama M (2007) Predictive factors of efficacy of leucocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liv Dis 39: 422–429Google Scholar
  92. Tan T, Lawrance IC (2009) Use of mycophenolate mofetil in inflammatory bowel disease. World J Gastroenterol 15: 1594–1599PubMedGoogle Scholar
  93. Travis SPL, Stange EF, Lemann M et al. (2008) European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn Colitis 2: 24–62Google Scholar
  94. Turner D, Otley AR, Mack D et al. (2007) Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133: 423–432PubMedGoogle Scholar
  95. Turner D, Walsh CM, Benchimol EI et al. (2008) Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 57: 331–338PubMedGoogle Scholar
  96. Turner D, Travis SPL, Griffiths AM et al. (2011) Consensus for the management acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group. Am J Gastroenterol 106: 574–588PubMedGoogle Scholar
  97. Vernier-Massouille G, Balde M, Salleron J et al. (2008) Natural history of pediatric Crohn’s disease: a population based cohort study. Gastroenterology 135: 1106–1113PubMedGoogle Scholar
  98. Walker TR Land ML, Kartashov A et al. (2007) Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44: 414–422Google Scholar
  99. Wewer V, Hesselfeldt P, Qvuist N et al. (2005) J-pouch ileoanal anastomosis in children and adolescents with ulcerative colitis: functional outcome, satisfaction and impact on social life. J Pediatr Gastroenterol Nutr 40: 189–193PubMedGoogle Scholar
  100. Wilschanski M, Chait P, Wade JA et al. (1995) Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 22: 1415–1422PubMedGoogle Scholar
  101. Wilson DC, Thomas AG, Croft NM (2010) Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 50(Suppl 1): S14–S34Google Scholar
  102. Winter KV, Jess T, Langholz E et al. (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen county. Clin Gastroenterol Hepatol 2: 1088–1095Google Scholar
  103. Zaag-Loonen HJ van der, Casparie M, Taminiau JAJM et al. (2004a) The incidence of pediatric inflammatory bowel disease in the Netherlands: 1999-2001. J Pediatr Gastroenterol Nutr 38: 302–307Google Scholar
  104. Zaag-Loonen HJ van der, Grootenhuis MA, Last BF et al. (2004b) Coping strategies and quality of life of adolescents with inflammatory bowel disease. Qual Life Res 13: 1011–1019Google Scholar
  105. Ziring DA, Wu SS, Mow WS et al. (2007) Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 45: 306–311PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Michael Friedt
    • 1
  • Christian P. Braegger
    • 2
  1. 1.Klinik für allgemeine PädiatrieUniversitätsklinikum DüsseldorfDüsseldorfDeutschland
  2. 2.Abteilung Gastroenterologie und ErnährungUniversitäts-Kinderkliniken, Kinderspital ZürichZürichSchweiz

Personalised recommendations